Advanced NanoTherapies has closed a US$7.2 million Series A equity financing round marking a total of US$12.5 million raised since September 2020. Funds will be used to complete the first-in-human clinical study in Australia of the SirPlux Duo drug-coated balloon (DCB) in de novo coronary artery disease (CAD) lesions. Funding comes from sources in the USA, Canada, Europe and Asia.
“Interventional therapies have historically advanced in big steps—angioplasty, bare-metal stenting, drug-eluting stenting,” says Reggie Groves a member of the board of directors at Advanced NanoTherapies. “We believe the interventional cardiology space is poised for the next disruption in the treatment of coronary artery disease with the unique offering of the SirPlux Duo DCB. We are pleased to initiate the next phase of Advanced NanoTherapies’ clinical program.”
“With the advent of cutting-edge drug delivery platforms, it is no longer acceptable to deliver drugs to arterial tissue using a haphazard, undirected approach,” stated Aloke Finn (University of Maryland, College Park, USA). “SirPlux Duo will be the first dual active pharmaceutical ingredient (API) solution to provide a fully targeted, safe, and potent drug delivery option for preventing neointimal growth after coronary and peripheral interventions.”
The SirPlux Duo DCB combines the synergistic power of Sirolimus and Paclitaxel to create a next-generation, front-line therapy engineered to provide stent-like patency and restenosis prevention while leaving no implant behind, Advanced NanoTherapies said in a press release. The company adds that SirPlux Duo DCB delivers low-dose, long-term release of both compounds to inhibit cell growth, resulting in maximum potency exceeding any other DCB or drug-eluting stent. The Advanced NanoTherapies nanoparticle drug-encapsulation and delivery platform provides safe, reliable, and sustained bioavailability of the two synergistic drugs in tissue, it states.
“Sirolimus and paclitaxel are both proven drugs in the vascular space, each with unique benefits, limitations, and mechanisms of action,” commented Mehdi Shishehbor (Case Western Reserve University School of Medicine, Cleveland, Ohio) and chief medical officer of Advanced NanoTherapies. “Pre-clinical data have shown that using both drugs in combination results in higher antiproliferative potency at lower doses than using each drug independently. The synergistic effects of eluting them simultaneously over long periods may be the key to sustaining patency following interventions.”
“We are excited to close this round as we prepare for clinical testing of the SirPlux Duo DCB in de novo CAD patients,” said Marwan Berrada, co-founder and CEO of Advanced NanoTherapies. “Thank you to everyone involved in helping us reach this important milestone. The Series A funding will allow us to gather first-in-human clinical data before the end of 2022, a key step to accelerating the paradigm shift of leaving nothing behind in coronary arteries.”